Screener
Gilead Sciences GILD Europe — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Total Oncology | 468 | 265 | 140 | 873 | 427 | 291 | 131 | 849 |
| Other | ||||||||
| AmBisome | 4 | 47 | 59 | 110 | 7 | 65 | 56 | 129 |
| Other(5) | 22 | 8 | 21 | 51 | 44 | 8 | 21 | 73 |
| Total Other | 26 | 55 | 80 | 161 | 52 | 73 | 77 | 202 |
| Total product sales | 5,601 | 1,155 | 872 | 7,627 | 5,038 | 1,178 | 838 | 7,054 |
| Royalty, contract and other revenues | 2 | 169 | 4 | 176 | 13 | 10 | 4 | 27 |
| Total revenues | $5,603 | $1,324 | $876 | $7,803 | $5,051 | $1,189 | $842 | $7,082 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's europe — total revenues?
- Gilead Sciences (GILD) reported europe — total revenues of $1.32B in Q2 2026.
- How has Gilead Sciences's europe — total revenues changed year-over-year?
- Gilead Sciences's europe — total revenues increased by 11.4% year-over-year, from $1.19B to $1.32B.
- What is the long-term trend for Gilead Sciences's europe — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's europe — total revenues has grown at a 1.0% compound annual growth rate (CAGR), from $4.87B to $5.06B.
- What does europe — total revenues mean?
- This metric represents the total gross income generated from the sale of pharmaceutical products and services within the European geographic market. It reflects the commercial success and market penetration of the company's therapeutic portfolio, including HIV, oncology, and liver disease treatments, across this specific region. Monitoring this figure helps assess the company's regional growth trajectory and its ability to navigate local regulatory and pricing environments.
Ask your AI about Gilead Sciences's europe — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude